Presentation is loading. Please wait.

Presentation is loading. Please wait.

Hematologic Safety Profile of Linezolid in the Early Periengraftment Period after Allogeneic Stem Cell Transplantation  Nina Cohen, Coralia N. Mihu, Susan.

Similar presentations


Presentation on theme: "Hematologic Safety Profile of Linezolid in the Early Periengraftment Period after Allogeneic Stem Cell Transplantation  Nina Cohen, Coralia N. Mihu, Susan."— Presentation transcript:

1 Hematologic Safety Profile of Linezolid in the Early Periengraftment Period after Allogeneic Stem Cell Transplantation  Nina Cohen, Coralia N. Mihu, Susan K. Seo, Dick Chung, Joanne Chou, Glenn Heller, Genovefa A. Papanicolaou  Biology of Blood and Marrow Transplantation  Volume 15, Issue 10, Pages (October 2009) DOI: /j.bbmt Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Cumulative incidence for ANC 500 by treatment group. The solid line represents linezolid; the dashed line, vancomycin. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Cumulative incidence for PLT 20 by treatment group. The solid line represents linezolid; the dashed line, vancomycin. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions


Download ppt "Hematologic Safety Profile of Linezolid in the Early Periengraftment Period after Allogeneic Stem Cell Transplantation  Nina Cohen, Coralia N. Mihu, Susan."

Similar presentations


Ads by Google